GeneticsNow® Series

This COMPREHENSIVE GERMLINE PANEL analyzes 88 clinically-relevant genes that are associated with genetic disorders, including most hereditary cancers.

PROSTATENOW is a germline test for people with prostate cancer. This test can be used to predict prognosis among men with localized prostate cancer, predict therapeutic responses for advanced patients, and predict cancer risk among unaffected men.

There is an increased likelihood of a BRCA1 or BRCA2 mutation in patients with certain personal and family history characteristics and various clinical criteria. BRCANOW is a Next-Gen Sequencing (NGS)-based assay using a state-of-the-art platform to detect whether or not a mutation is present.

LYNCHNOW is a cost-effective, screening tool that rapidly detects mutations that cause Lynch syndrome.